Imatinib is not a potential alternative treatment for uterine leiomyosarcoma.
César
C
Serrano
Carlos
C
Mackintosh
David
D
Herrero
Ana S
AS
Martins
Enrique
E
de Alava
Teresa
T
Hernández
José
J
Pérez-Fontán
Mar
M
Abad
Angustias
A
Pérez
Eugenio
E
Serrano
Agustín
A
Bullón
Alberto
A
Orfao
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D015153:Blotting, Western; D004252:DNA Mutational Analysis; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry; D007890:Leiomyosarcoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D010879:Piperazines / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit